Haemonetics (NYSE:HAE – Get Free Report) had its target price lifted by stock analysts at Citizens Jmp from $115.00 to $144.00 in a research note issued on Monday, Benzinga reports. The firm currently has a “market outperform” rating on the medical instruments supplier’s stock. Citizens Jmp‘s price target would suggest a potential upside of 16.92% from the stock’s previous close.
HAE has been the subject of several other research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research note on Wednesday, November 4th. Barrington Research increased their target price on shares of Haemonetics from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Friday, November 6th. Citigroup raised their target price on Haemonetics from $123.00 to $149.00 and gave the company a “buy” rating in a report on Friday, November 6th. Robert W. Baird boosted their price target on Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research report on Friday, August 21st. Finally, JPMorgan Chase & Co. upped their price target on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $130.50.
Get Our Latest Stock Report on Haemonetics
Haemonetics Price Performance
Shares of HAE opened at $123.16 on Monday. The firm has a market cap of $5.61 billion, a PE ratio of 55.23, a PEG ratio of 2.46 and a beta of 0.62. The firm’s 50 day moving average price is $113.34 and its 200 day moving average price is $81.36. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.83 and a current ratio of 2.84. Haemonetics has a twelve month low of $51.00 and a twelve month high of $132.00.
Haemonetics (NYSE:HAE – Get Free Report) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, topping the consensus estimate of $1.29 by $0.06. The company had revenue of $357.76 million during the quarter, compared to the consensus estimate of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.27 earnings per share. As a group, research analysts expect that Haemonetics will post 5.32 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CAO Farris Maryanne Maunsell sold 836 shares of the stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total value of $101,147.64. Following the completion of the sale, the chief accounting officer owned 5,828 shares in the company, valued at approximately $705,129.72. This trade represents a 12.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.07% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Haemonetics
Hedge funds have recently made changes to their positions in the business. Entropy Technologies LP acquired a new stake in shares of Haemonetics during the 3rd quarter valued at about $2,134,000. Pathstone Holdings LLC bought a new stake in Haemonetics in the third quarter valued at about $215,000. Marshall Wace LLP raised its position in Haemonetics by 52.0% in the third quarter. Marshall Wace LLP now owns 46,344 shares of the medical instruments supplier’s stock worth $4,880,000 after purchasing an additional 15,851 shares in the last quarter. Empowered Funds LLC acquired a new position in Haemonetics in the third quarter worth about $1,624,000. Finally, First Trust Advisors LP raised its position in Haemonetics by 8.3% in the third quarter. First Trust Advisors LP now owns 68,637 shares of the medical instruments supplier’s stock worth $7,227,000 after purchasing an additional 5,279 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
Further Reading
- Five stocks we like better than Haemonetics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
